RNAi company OliX lists in Korea

OliX Pharmaceuticals Inc. (KOSDAQ:226950) raised KrW43.2 billion ($38.3 million) on July 18 through the sale of 1.2 million shares at KrW36,000 in an IPO underwritten by NH Investment & Securities.

Next half, OliX expects to complete a U.K. Phase I trial of OLX10010 to treat hypertrophic scars. The RNA interference therapeutic targets connective tissue growth factor (CTGF)...